SGMO — Sangamo Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $151.42m
- $121.81m
- $57.80m
Annual cashflow statement for Sangamo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -121 | -178 | -192 | -258 | -97.9 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 32.7 | 37.5 | 38.9 | 188 | 21.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 253 | -102 | -82.3 | -164 | 4.51 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 170 | -233 | -224 | -225 | -67.1 |
| Capital Expenditures | -14.7 | -23.3 | -20.2 | -21.2 | -0.267 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -257 | 271 | 79.5 | 175 | 37.8 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -272 | 248 | 59.3 | 154 | 37.5 |
| Financing Cash Flow Items | -0.765 | -3.26 | -2.1 | -1.45 | -0.904 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 153 | 32.9 | 84.7 | 14.6 | 28.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 50.9 | 47.5 | -78.4 | -55.2 | -3.29 |